These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 17686450

  • 1. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.
    Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS.
    Am J Ophthalmol; 2007 Oct; 144(4):533-40. PubMed ID: 17686450
    [Abstract] [Full Text] [Related]

  • 2. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.
    Okeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Friedman DS.
    Ophthalmology; 2009 Feb; 116(2):191-9. PubMed ID: 19084273
    [Abstract] [Full Text] [Related]

  • 3. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
    Robin AL, Covert D.
    Ophthalmology; 2005 May; 112(5):863-8. PubMed ID: 15878067
    [Abstract] [Full Text] [Related]

  • 4. Persistence and adherence with topical glaucoma therapy.
    Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM.
    Am J Ophthalmol; 2005 Oct; 140(4):598-606. PubMed ID: 16226511
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study.
    Quigley HA, Friedman DS, Hahn SR.
    Ophthalmology; 2007 Sep; 114(9):1599-606. PubMed ID: 17572498
    [Abstract] [Full Text] [Related]

  • 6. Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring.
    Hermann MM, Bron AM, Creuzot-Garcher CP, Diestelhorst M.
    J Glaucoma; 2011 Oct; 20(8):502-8. PubMed ID: 20852438
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS, Okeke CO, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Quigley HA.
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [Abstract] [Full Text] [Related]

  • 8. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring.
    Hermann MM, Papaconstantinou D, Muether PS, Georgopoulos G, Diestelhorst M.
    Acta Ophthalmol; 2011 Jun; 89(4):e300-5. PubMed ID: 21106046
    [Abstract] [Full Text] [Related]

  • 9. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
    Flowers B, Wand M, Piltz-Seymour J, Berke SJ, Day D, Teague J, Smoot TM, Landry TA, Bergamini MV, Mallick S, Travatan Dosing Aid Study Group.
    Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
    [Abstract] [Full Text] [Related]

  • 10. Determinants of adherence to glaucoma medical therapy in a long-term patient population.
    Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J.
    J Glaucoma; 2009 Mar; 18(3):238-43. PubMed ID: 19295380
    [Abstract] [Full Text] [Related]

  • 11. Accounting for restart rates in evaluating persistence with ocular hypotensives.
    Schwartz GF, Platt R, Reardon G, Mychaskiw MA.
    Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
    [Abstract] [Full Text] [Related]

  • 12. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R, Handrock R, Klebs S, Tousset E, Vrijens B.
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [Abstract] [Full Text] [Related]

  • 13. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE, Lai J.
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [Abstract] [Full Text] [Related]

  • 14. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
    McCarty CA, Mukesh BN, Kitchner TE, Hubbard WC, Wilke RA, Burmester JK, Patchett RB.
    J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
    [Abstract] [Full Text] [Related]

  • 15. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC, Konstas AG, Nelson LA, Kruft B.
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [Abstract] [Full Text] [Related]

  • 16. Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma.
    Holló G, Kóthy P, Géczy A, Vargha P.
    J Glaucoma; 2009 Jul; 18(4):288-92. PubMed ID: 19365193
    [Abstract] [Full Text] [Related]

  • 17. Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost.
    Lupinacci AP, Netland PA, Fung KH, Evans D, Zhao Y.
    Adv Ther; 2008 Mar; 25(3):231-9. PubMed ID: 18369537
    [Abstract] [Full Text] [Related]

  • 18. Determinants of medication adherence to topical glaucoma therapy.
    Dreer LE, Girkin C, Mansberger SL.
    J Glaucoma; 2012 Mar; 21(4):234-40. PubMed ID: 21623223
    [Abstract] [Full Text] [Related]

  • 19. Health literacy and adherence to glaucoma therapy.
    Muir KW, Santiago-Turla C, Stinnett SS, Herndon LW, Allingham RR, Challa P, Lee PP.
    Am J Ophthalmol; 2006 Aug; 142(2):223-6. PubMed ID: 16876500
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
    Chiselită D, Pentru Eastern European Start Study Group.
    Oftalmologia; 2007 Aug; 51(2):81-6. PubMed ID: 17937041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.